214 related articles for article (PubMed ID: 27218445)
21. deltaPKC participates in the endoplasmic reticulum stress-induced response in cultured cardiac myocytes and ischemic heart.
Qi X; Vallentin A; Churchill E; Mochly-Rosen D
J Mol Cell Cardiol; 2007 Oct; 43(4):420-8. PubMed ID: 17825316
[TBL] [Abstract][Full Text] [Related]
22. Phosphoinositide-dependent kinase-1 and protein kinase Cδ contribute to endothelin-1 constriction and elevated blood pressure in intermittent hypoxia.
Webster BR; Osmond JM; Paredes DA; DeLeon XA; Jackson-Weaver O; Walker BR; Kanagy NL
J Pharmacol Exp Ther; 2013 Jan; 344(1):68-76. PubMed ID: 23093023
[TBL] [Abstract][Full Text] [Related]
23. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle.
Piao L; Fang YH; Cadete VJ; Wietholt C; Urboniene D; Toth PT; Marsboom G; Zhang HJ; Haber I; Rehman J; Lopaschuk GD; Archer SL
J Mol Med (Berl); 2010 Jan; 88(1):47-60. PubMed ID: 19949938
[TBL] [Abstract][Full Text] [Related]
24. Targeting the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis to discover potent PDK inhibitors through structure-based virtual screening and pharmacological evaluation.
Gan L; Yang Y; Liang Z; Zhang M; He Y; Zhang SL
Eur J Med Chem; 2024 Jan; 264():116008. PubMed ID: 38056298
[TBL] [Abstract][Full Text] [Related]
25. Translocation of deltaPKC to mitochondria during cardiac reperfusion enhances superoxide anion production and induces loss in mitochondrial function.
Churchill EN; Szweda LI
Arch Biochem Biophys; 2005 Jul; 439(2):194-9. PubMed ID: 15963450
[TBL] [Abstract][Full Text] [Related]
26. Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion.
Churchill EN; Ferreira JC; Brum PC; Szweda LI; Mochly-Rosen D
Cardiovasc Res; 2010 Jan; 85(2):385-94. PubMed ID: 19820255
[TBL] [Abstract][Full Text] [Related]
27. Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats.
Qi X; Inagaki K; Sobel RA; Mochly-Rosen D
J Clin Invest; 2008 Jan; 118(1):173-82. PubMed ID: 18097471
[TBL] [Abstract][Full Text] [Related]
28. Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats.
Miyaji Y; Walter S; Chen L; Kurihara A; Ishizuka T; Saito M; Kawai K; Okazaki O
Drug Metab Dispos; 2011 Oct; 39(10):1946-53. PubMed ID: 21712433
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo.
Inagaki K; Chen L; Ikeno F; Lee FH; Imahashi K; Bouley DM; Rezaee M; Yock PG; Murphy E; Mochly-Rosen D
Circulation; 2003 Nov; 108(19):2304-7. PubMed ID: 14597593
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer.
Sradhanjali S; Reddy MM
Curr Top Med Chem; 2018; 18(6):444-453. PubMed ID: 29788890
[TBL] [Abstract][Full Text] [Related]
31. Suppression of deltaPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia.
Shimohata T; Zhao H; Sung JH; Sun G; Mochly-Rosen D; Steinberg GK
J Cereb Blood Flow Metab; 2007 Aug; 27(8):1463-75. PubMed ID: 17293847
[TBL] [Abstract][Full Text] [Related]
32. Activation of protein kinase C delta by ψδRACK peptide promotes embryonic stem cell proliferation through ERK 1/2.
Garavello NM; Pena DA; Bonatto JM; Duarte ML; Costa-Junior HM; Schumacher RI; Forti FL; Schechtman D
J Proteomics; 2013 Dec; 94():497-512. PubMed ID: 24332066
[TBL] [Abstract][Full Text] [Related]
33. Activating deltaPKC antagonizes the protective effect of ERK1/2 inhibition against stroke in rats.
Castañeda D; Zhao H; Mochly-Rosen D; Steinberg GK
Brain Res; 2009 Jan; 1251():256-61. PubMed ID: 19063870
[TBL] [Abstract][Full Text] [Related]
34. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
35. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
[TBL] [Abstract][Full Text] [Related]
36. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase.
Korotchkina LG; Patel MS
J Biol Chem; 2001 Oct; 276(40):37223-9. PubMed ID: 11486000
[TBL] [Abstract][Full Text] [Related]
37. deltaPKC inhibition or varepsilonPKC activation repairs endothelial vascular dysfunction by regulating eNOS post-translational modification.
Monti M; Donnini S; Giachetti A; Mochly-Rosen D; Ziche M
J Mol Cell Cardiol; 2010 Apr; 48(4):746-56. PubMed ID: 19913548
[TBL] [Abstract][Full Text] [Related]
38. Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts.
Tanaka M; Terry RD; Mokhtari GK; Inagaki K; Koyanagi T; Kofidis T; Mochly-Rosen D; Robbins RC
Circulation; 2004 Sep; 110(11 Suppl 1):II194-9. PubMed ID: 15364862
[TBL] [Abstract][Full Text] [Related]
39. An inhibitor of the δPKC interaction with the d subunit of F1Fo ATP synthase reduces cardiac troponin I release from ischemic rat hearts: utility of a novel ammonium sulfate precipitation technique.
Ogbi M; Obi I; Johnson JA
PLoS One; 2013; 8(8):e70580. PubMed ID: 23936451
[TBL] [Abstract][Full Text] [Related]
40. Regulation of Pyruvate Dehydrogenase Kinase 4 in the Heart through Degradation by the Lon Protease in Response to Mitochondrial Substrate Availability.
Crewe C; Schafer C; Lee I; Kinter M; Szweda LI
J Biol Chem; 2017 Jan; 292(1):305-312. PubMed ID: 27856638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
